Peking University Cancer Hospital & Institute

This early-phase study tests a combination of a radioactive drug ([225Ac]Ac-DOTATATE) and an immunotherapy (tislelizumab) as maintenance therapy for people with extensive-stage small cell lung cancer that has a specific marker (SSTR). The goal is to see if this combination is saf…

This study tests a combination of chemotherapy drugs and an immunotherapy drug for a rare and aggressive type of stomach cancer called hepatoid adenocarcinoma. About 30 people with locally advanced, HER2-negative cancer will receive the treatment before and after surgery. The goa…

This study is testing a drug called sacituzumab govitecan (Trop-2 ADC) in 100 breast cancer patients whose cancer has spread to the brain. Researchers want to see if the drug can shrink brain tumors and delay disease progression, while also monitoring side effects. The study coll…

This study is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy before and after surgery can help patients with locally advanced esophageal cancer. About 30 participants will receive three cycles of the combination before surgery, then continue ad…

This study tests whether combining the drug camrelizumab with chemotherapy before surgery can help people with esophageal cancer keep their esophagus instead of having it removed. About 283 adults with early-stage esophageal cancer will receive the treatment and be monitored for …

This study tests a combination of three drugs (RC48, SOX, and Sindilizumab) given before and after surgery for a rare and aggressive stomach cancer called hepatoid adenocarcinoma. The goal is to see if this approach can shrink tumors and improve outcomes. About 30 participants wi…

This study is testing a new type of PET scan that uses a radioactive tracer to detect a protein called TROP2 on breast cancer cells. The goal is to see if this scan can predict how well a targeted drug (ADC therapy) will work for each patient. About 60 adults with breast cancer w…

This early-phase trial is testing a new radioactive imaging agent called 68Ga/18F-CAIX-LT-BCH to see if it can better detect clear cell renal cell carcinoma, a common type of kidney cancer. The study involves 3 participants who will receive the agent and undergo a PET/CT scan. Th…

This study tests a new PET imaging method that uses a radioactive tracer to spot HER2 proteins on breast cancer cells. The goal is to see if the scan can predict how well patients will respond to antibody-drug conjugate therapy. Researchers will enroll 50 adults with HER2-positiv…

This study tests a new imaging probe called 89Zr-s-C1 that attaches to a protein (MUC18) found on some solid tumors. The goal is to see if this PET/CT scan can find tumors that standard scans miss. About 20 adults with newly diagnosed or recurring solid tumors (like melanoma or s…

This study tests a new PET scan that uses a special tracer to find a protein called CLDN18.2 on solid tumors. The goal is to see if this scan can help identify which patients might benefit from treatments that target this protein. About 15 adults with solid tumors will receive th…

This study tests a new radioactive tracer called 68Ga-N188 that targets a protein called nectin-4, often found on urothelial cancer cells. Researchers will use PET/CT scans to see how well this tracer spots tumors in 20 people with recurrent or advanced bladder cancer. The goal i…

This study tests whether a traditional Chinese medicine formula called modified Bufei Decoction can reduce cough, fatigue, and shortness of breath in elderly patients who have had lung cancer surgery. About 174 participants will receive either the herbal granules or a placebo twi…

This study looks at whether people with early-stage lung cancer (stage IA2 to II) who have no detectable cancer DNA in their blood after surgery can safely skip additional treatments like chemotherapy. Instead, they would be closely monitored with regular blood tests and scans. T…